Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

IBB vs. BIB: which is better?

Bottom line

IBB vs BIB: the short answer

IBB (iShares Biotechnology ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 44% by weight.

IBB is cheaper at 0.44% vs 0.95% — a difference of $51 a year per $10,000 invested.

Over five years, IBB returned +2.5% a year vs −1.0% for BIB.

Updated Nov 19, 2026

IBB vs BIB side by side

IBBBIB
TypeETFETF
Fund familyiSharesProShares
CategoryTechnology SectorTechnology Sector
Expense ratio0.44%0.95%
Annual cost per $10k$44$95
10-yr cost on $10k (prospectus)$555$1,401
Max front loadNoneNone
12b-1 fee0%—
1-yr return+28.0%+59.3%
5-yr return (annualized)+2.5%−1.0%
10-yr return (annualized)+4.4%+1.4%
Best quarter+26.8%+56.2%
Worst quarter−22.9%−42.7%
Net assets (fund)$5.9B$73.7M
Number of holdings254267
Portfolio turnover27%29%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearIBBBIBDifference
2025+28.0%+59.3%−31.3%
2024−2.4%−10.0%+7.6%
2023+3.6%−1.3%+4.9%
2022−13.6%−28.6%+15.0%
2021+1.0%−5.9%+6.9%
2020+25.9%+39.7%−13.8%
2019+24.8%+45.5%−20.8%
2018−9.1%−24.4%+15.2%
2017+21.2%+40.8%−19.6%
2016−21.5%−44.2%+22.7%

Source: Fund prospectus bar charts

Holdings overlap

12 of IBB's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingIBBBIB
Vertex Pharmaceuticals, Inc.7.66%4.65%
Gilead Sciences, Inc.7.52%4.66%
Amgen, Inc.7.50%4.48%
Regeneron Pharmaceuticals, Inc.5.70%3.21%
Alnylam Pharmaceuticals, Inc.5.68%2.01%
Argenx SE3.15%1.19%
Insmed, Inc.2.95%1.16%
Biogen, Inc.2.03%1.44%
United Therapeutics Corp.1.82%1.22%
Incyte Corp.1.62%0.97%
Illumina, Inc.1.41%1.25%
Moderna, Inc.0.88%0.94%

Source: SEC Form N-PORT

IBB top 10

  1. BlackRock Funds III — 13.18%
  2. Vertex Pharmaceuticals, Inc. — 7.66%
  3. Gilead Sciences, Inc. — 7.52%
  4. Amgen, Inc. — 7.50%
  5. Regeneron Pharmaceuticals, Inc. — 5.70%
  6. Alnylam Pharmaceuticals, Inc. — 5.68%
  7. IQVIA Holdings, Inc. — 3.18%
  8. Argenx SE — 3.15%
  9. Insmed, Inc. — 2.95%
  10. Mettler-Toledo International, Inc. — 2.49%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between IBB and BIB?
IBB (iShares Biotechnology ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 44% by weight. IBB is cheaper at 0.44% vs 0.95% — a difference of $51 a year per $10,000 invested.
Which is cheaper, IBB or BIB?
IBB has the lower expense ratio (0.44%).
Should I own both IBB and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.